Miromatrix Medical Inc. (MIRO) Q2 2023 Earnings Call Transcript

Miromatrix Medical Inc. (NASDAQ:MIRO) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET

Company Participants

Max Forgan – Gilmartin Investor Relations

Jeff Ross – Chief Executive Officer

Jim Douglas – Chief Financial Officer

Conference Call Participants

Alex Nowak – Craig-Hallum

Phillip Dantoin – Piper Sandler


Good day, and welcome to the Miromatrix Medical, Inc. Second Quarter 2023 Earnings Conference Call. All participants’ will be in listen-only mode. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Max Forgan with Gilmartin Investor Relations. Please go ahead.

Max Forgan

Good afternoon and thank you for joining us. Earlier today, Miromatrix released financial results for the quarter ended June 30, 2023. The release is currently available on the company’s website at www.miromatrix.com. Jeff Ross, Chief Executive Officer; and Jim Douglas, Chief Financial Officer, will host this afternoon’s call.

Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical fact, including statements regarding the potential timing of pre-IND and IND filings, and the initiation of related clinical trials, future expenses and revenue, capital requirements, cash runway and needs for additional financing should be deemed to be forward-looking statements. All forward-looking statements are based upon current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results to differ materially from those anticipated or implied by these forward-looking statements.

Accordingly, you should not place undue reliance on these statements. For a list and descriptions of the material risks and

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *